- Home
- GFAI vs TOVX Comparison
GFAI vs TOVX Comparison
Compare GFAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- TOVX
- Stock Information
- Founded
- GFAI 2018
- TOVX 2001
- Country
- GFAI Singapore
- TOVX United States
- Employees
- GFAI N/A
- TOVX N/A
- Industry
- GFAI Diversified Commercial Services
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- TOVX Health Care
- Exchange
- GFAI Nasdaq
- TOVX Nasdaq
- Market Cap
- GFAI 23.3M
- TOVX 3.8M
- IPO Year
- GFAI N/A
- TOVX 2006
- Fundamental
- Price
- GFAI $1.22
- TOVX $0.50
- Analyst Decision
- GFAI Strong Buy
- TOVX Hold
- Analyst Count
- GFAI 1
- TOVX 1
- Target Price
- GFAI $4.50
- TOVX N/A
- AVG Volume (30 Days)
- GFAI 455.0K
- TOVX 183.1K
- Earning Date
- GFAI 04-28-2025
- TOVX 08-12-2025
- Dividend Yield
- GFAI N/A
- TOVX N/A
- EPS Growth
- GFAI N/A
- TOVX N/A
- EPS
- GFAI N/A
- TOVX N/A
- Revenue
- GFAI $36,347,373.00
- TOVX N/A
- Revenue This Year
- GFAI $5.66
- TOVX N/A
- Revenue Next Year
- GFAI $4.69
- TOVX N/A
- P/E Ratio
- GFAI N/A
- TOVX N/A
- Revenue Growth
- GFAI 0.18
- TOVX N/A
- 52 Week Low
- GFAI $0.76
- TOVX $0.40
- 52 Week High
- GFAI $3.88
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- GFAI 57.19
- TOVX 45.57
- Support Level
- GFAI $1.14
- TOVX $0.42
- Resistance Level
- GFAI $1.24
- TOVX $0.48
- Average True Range (ATR)
- GFAI 0.07
- TOVX 0.03
- MACD
- GFAI 0.00
- TOVX 0.02
- Stochastic Oscillator
- GFAI 78.57
- TOVX 88.67
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.